Latest Ratios: P/E Ratio -5.1x · EV/EBITDA N/A · ROE -52.6%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $479M | $339M | $221M | $101M | $63M | $109M | $27M | $18M | $25M | $47M | $25M |
| Enterprise Value | $386M | $246M | $153M | $88M | $-87278990 | $83M | $17M | $6M | $27M | $42M | $21M |
| P/E Ratio → | -5.07 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.33 | 2.09 | 1.83 | 0.87 | 0.42 | 4.19 | 3.63 | 10.04 | — | 5.47 | 2.82 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.6% | -52.6% | -57.7% | -39.0% | -46.8% | -124.9% | -446.0% | -1736.1% | -1307.7% | -234.4% | -167.6% |
| ROA | -48.3% | -48.3% | -53.4% | -37.5% | -42.1% | -78.0% | -175.2% | -412.3% | -454.8% | -188.3% | -134.8% |
| ROIC | -97.9% | -97.9% | -68.0% | -82.4% | — | — | — | — | -2293.3% | -344.7% | -256.4% |
| ROCE | -55.7% | -55.7% | -58.3% | -41.7% | -43.9% | -94.6% | -353.4% | -40579.3% | -1124.1% | -225.4% | -159.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.00 | 0.55 | 0.06 | 0.01 | — | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.57 | -0.56 | -0.12 | -1.01 | -1.02 | -1.30 | -6.60 | — | -0.52 | -0.45 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -21.72 | -54.74 | — | -5.14 | -42.33 | -12711.94 | -2962.99 |
Net cash position: cash ($94M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.37 | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 | 1.45 | 0.32 | 2.78 | 2.60 |
| Quick Ratio | 14.37 | 14.37 | 13.39 | 20.18 | 61.78 | 21.34 | 3.26 | 1.45 | 0.32 | 2.78 | 2.60 |
| Cash Ratio | 14.09 | 14.09 | 13.21 | 19.60 | 61.09 | 20.86 | 3.09 | 1.38 | 0.26 | 2.53 | 2.35 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $76M | $51M | $51M | $19M | $8M | $6M | $2M | $1M | $825934 | $495464 |
Clinical trial funding dependency
Based on reported figures, Rezolute trades at a price-to-book ratio of 2.36, which appears to discount the company's clinical-stage status relative to peers like XOMA, suggesting that investors are currently prioritizing the immediate cash runway over the long-term potential of the RZ358 and RZ402 pipeline assets.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's pre-revenue nature, making traditional valuation metrics largely irrelevant for assessing intrinsic value. Investors should monitor whether the current P/B multiple expands as the company approaches potential regulatory milestones, or if it continues to compress due to persistent equity dilution.
As reported in financial statements, Rezolute's ROIC has consistently remained in negative territory, reaching -11.6% in 2026Q3, which highlights the structural challenge of generating returns on invested capital while the firm remains entirely dependent on external funding to sustain its high-intensity clinical research and development activities.
The persistent negative ROIC is an expected outcome for a biotech firm in the clinical development stage, but it warrants caution regarding the efficiency of capital allocation. Without commercial revenue to offset R&D costs, the company's ability to compound value remains entirely contingent on the successful clinical validation of its lead candidates.
According to recent SEC filings, Rezolute's current ratio has fluctuated significantly, dropping from 15.84 in 2026Q3 to lower levels in previous periods, which indicates that while the firm maintains a high short-term liquidity position, the rapid cash burn rate threatens to erode this buffer before commercialization.
The high current ratio is primarily a function of cash on hand rather than operational working capital efficiency. Investors should interpret this liquidity as a finite runway rather than a sign of operational health, as the lack of revenue means that every dollar spent on clinical trials directly reduces the company's survival horizon.
Based on an analysis of the company's financial structure, the current ratio is the most commonly misapplied metric for Rezolute, as it obscures the reality that the firm's assets are not working capital but rather a rapidly depleting pool of cash intended to fund clinical trial milestones.
Using the current ratio to assess solvency in a pre-revenue biotech is misleading because it ignores the lack of recurring cash inflows. A more appropriate metric for this business model would be the 'cash burn rate' or 'months of runway,' which provides a clearer picture of the company's proximity to a potential liquidity crisis.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RZLT stock.
Rezolute, Inc.'s current P/E ratio is -5.1x. This places it at the 50th percentile of its historical range.
Rezolute, Inc.'s return on equity (ROE) is -52.6%. The historical average is -146.2%.
Based on historical data, Rezolute, Inc. is trading at a P/E of -5.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.